Apollo Therapeutics and King’s College London collaborate for translational biology and drug development

pharmafile | February 22, 2022 | News story | Manufacturing and Production  

Apollo Therapeutics has expanded its partnerships with world-leading UK research institutions, entering into a strategic collaboration with King’s College, London. King’s now joins Imperial College, UCL, and the University of Cambridge as one of Apollo’s top global research partners.

Apollo Therapeutics is a biopharmaceutical company focused on translational biology, and asset-centric drug development. The collaboration between Apollo and King’s will leverage the strengths of each organisation with a focus on developing novel therapeutics for patients across multiple disease areas.

“Translating our biomedical research into effective therapies that improve health is a key priority for King’s researchers. I am delighted that this new partnership with Apollo will provide new routes for us to achieve this goal,” said Professor Reza Razavi, Vice President (Research) at King’s College London. “Apollo has an excellent track record in partnering with academics to progress their discoveries into therapies. King’s researchers are looking forward to working with Apollo to progress promising therapeutic programs into their drug discovery pipeline and on to clinical impact.”

King’s College has one of the leading scientific discovery portfolios worldwide, and aims to contribute biological research breakthroughs, with the potential to create high-impact medicines.

“When looking at research output, King’s College London is one of the largest and most successful centres for biomedical research and education in the UK and indeed globally. With its broad clinical presence, we have also found King’s has exceptional insight in selecting and advancing research that can translate effectively into therapeutic programs,” said Dr Richard Mason, chief executive officer of Apollo. “We are proud to initiate this partnership with our newest collaborator as we look to grow both our portfolio of programs and our relationships with the world’s leading scientists and biomedical institutions. This collaboration continues to build on recent the progress we have made in advancing our internal pipeline, building our team and establishing our US operations in Cambridge, Mass.”

Ana Ovey

Related Content

No items found

Latest content